Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse
Ayat Zagzoog, Kenzie Halter, Nini Ha, Alayna M. Jones, Rachel Andres, Andy Kim, Deborah Michel, Jane Alcorn, Robert B. Laprairie · 2025
Read Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse by Ayat Zagzoog, Kenzie Halter, Nini Ha, Alayna M. Jones, Rachel Andres, Andy Kim, Deborah Michel, Jane Alcorn, Robert B. Laprairie (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722920.txt.
Description
Ayat Zagzoog and co-authors chart how the body handles cannabigerol, a minor cannabis compound, in mice in a study from 2025. THC, the main cannabis compound, causes the classic high through a brain receptor. CBG shows promise for anxiety and other uses, but its basic pharmacology is poorly known.
Mice of a standard lab strain got CBG by mouth, by injection into the belly, or into a vein. Blood samples at set times traced how fast the compound rose and fell. Behavior tests then measured its effects on the body and brain. The team expected fewer effects than THC at matched exposure. A clear map of CBG's path through the body guides future medical studies.
Catalog record
| CREATOR | Ayat Zagzoog, Kenzie Halter, Nini Ha, Alayna M. Jones, Rachel Andres, Andy Kim, Deborah Michel, Jane Alcorn, Robert B. Laprairie |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |